74 Views | 76 Downloads
Christopher B. Doering, PhD, 2015 Uppergate Drive, Emory Children’s Center, Rm 450, Atlanta, GA 30322, USA. cdoerin@emory.edu
Conceptualization, A.L.R., H.T.S., S.C., and C.B.D.; methodology, C.P., G.D., K.A.K., J.S.A., H.T.S., S.C., and C.B.D.; investigation, A.L.R., C.P., T.S.L., K.A.K., J.T.Z., and G.D.; validation, A.L.R.; formal analysis, A.L.R.; resources, J.A.; writing – original draft, A.L.R.; writing – review & editing, A.L.R., H.T.S., S.C., and C.B.D.; visualization, A.L.R.; supervision, S.C. and C.B.D.; funding acquisition, H.T.S., S.C., and C.B.D.
C.B.D. and H.T.S. are co-founders of Expression Therapeutics and own equity in the company. Expression Therapeutics owns the intellectual property associated with ET3. G.D. is an employee of Expression Therapeutics and owns equity in the company. S.C. serves on the advisory committee on emapalumab for Sobi. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. A.L.R., C.P., T.S.L., K.A.K., J.T.Z., and J.S.A. declare no competing interests.
This work was supported by funding from the National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (NHLBI) (C.B.D. and H.T.S.) grant number U54 HL141981 and Hemophilia of Georgia (C.B.D. and H.T.S.).
Research reported in this publication was supported in part by the Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta, and NIH/NCI under award number P30CA138292.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Graphical abstract and original schematic figures created with https://biorender.com/.
© 2021 The Authors